Trial reportJournal of clinical hypertension (Greenwich, Conn.)2025
Dyslipidemia Impacts Cardiometabolic Health and CVD Risk in a Relatively Young Otherwise Healthy Population.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06544915 (Evaluating the Effects of a Synbiotic Versus Probiotic or Placebo on Gut Microbiota and Cardiometabolic Health), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Effects of a Synbiotic Versus Probiotic or Placebo on Gut Microbiota and Cardiometabolic Health: A Randomized Double-Blind Placebo Controlled Trial
Who cites it
5 citing papers in PubMed.
- Review
- Association between insulin resistance surrogate markers and cardiovascular disease risk in individuals with subclinical metabolic disorders: a prospective cohort study based on baseline levels, cumulative exposure, and longitudinal trajectories.Cardiovascular diabetology · 2026Article
- The simplified method for quantifying metabolic syndrome (siMS) score reflects an increased cardiometabolic burden: adiposity, hemodynamics, and HRV findings in young adults.Journal of diabetes and metabolic disorders · 2026Article
- Is Crocin Effective in Modulating Blood Lipid Levels? An Updated Systematic Review and Meta-Analysis with Dose- and Time-Response Assessments.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Association between volatile organic compounds in urine and dyslipidemia: findings based on analysis of NHANES data.Lipids in health and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dyslipidemia, abnormal levels of lipids in the bloodstream, is associated with cardiovascular disease risk (CVD). The purpose of this study was to evaluate the effects of dyslipidemia on cardiometabolic health in relatively young, healthy adults. Participants were 54 healthy males and females aged 18-60 years. Participants were assessed for anthropometrics, body composition, blood pressure and vascular stiffness indicators, microvascular health, and glucose and lipid levels. Using a cross-sectional approach, participants were characterized and grouped as having dyslipidemia or not, and then statistically assessed to determine whether differences in other cardiometabolic health measures existed between the groups. There were significant differences between groups for body weight and composition (total mass, muscle mass, visceral fat, bone mass, and body mass index, all, p < 0.027, Cohen's d > 0.605) with the dyslipidemia group being higher. There were significant differences between groups for peripheral and central blood pressures (all, p < 0.003, Cohen's d > 0.899), as well as for vascular stiffness indicators (pulse pressure, augmentation pressure, augmentation index, augmentation index 75) (all, p < 0.022, Cohen's d > 0.672) with elevations noted in the dyslipidemia group. Ten-year CVD risk was significantly different between groups, with an average risk of 0.8% in the normal lipids group and a risk of 5.4% in the dyslipidemia group (p < 0.001, Cohen's d = 1.260). However, there were no significant differences in macro- or micronutrient intake between groups (all, p > 0.166, Cohen's d < 0.412). There is a significant impact on cardiometabolic health in individuals with dyslipidemia who are otherwise healthy, which may increase individual risk for CVD. Trial Registration: ClinicalTrials.gov identifier: NCT06544915.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.